Jeffrey Joyce CV 11-8-12 - Kansas City University of Medicine and ...
Jeffrey Joyce CV 11-8-12 - Kansas City University of Medicine and ... Jeffrey Joyce CV 11-8-12 - Kansas City University of Medicine and ...
Jeffrey N. Joyce, Ph.D. December 2012Symposium on Cerebral Glood Flow & Metabolism, Baltimore MD.April 21, 1998, “Dopamine D3 receptor as a target of antipsychotics, “ Invited speaker,Neurosciences Program, University of Michigan, Ann Arbor, MI.July 16, 1998, “Molecular substrates of neurochemical disturbances in schizophrenia, “Symposium Chair, XXI CINP Congress, Glasgow Scotland.July 21, 1998, “Extrapyramidal symptoms in Alzheimer’s disease: Underlying mechanisms,”Invited Speaker, Molecular and Cellular Biology Lecture Series, University ofManchester, Manchester EnglandJuly 25, 1998, “Dopamine D3 receptors: Ontogeny and alterations in schizophrenia,” InvitedSpeaker, DA ’98, Strasbourg France.September 28, 1998, “Extrapyramidal symptoms in Alzheimer’s disease: Underlyingmechanisms,” Invited Speaker, Molecular and Cellular Biology Lecture Series, ArizonaState University, Tempe AZOctober 18-21, 1998, “D 3 receptors and the actions of neuroleptics in the ventral striatopallidalsystem of schizophrenics,” Invited Speaker, New York Academy of SciencesConference, Advancing From the Ventral Striatum to the Extended Amygdala:Implications for Neuropsychiatry and Drug Abuse, Charlottesville, VirginiaOctober 31- November 4, 1998, “Segregation and co-expression of D 2 and D 3 receptors in thebrain of schizophrenic patients: postmortem studies,” Invited Speaker, Symposia: TheDopamine Hypothesis of Schizophrenia Revisited, European College ofNeuropschopharmacology, Paris, FranceMarch 16, 1999, “The dopamine D 3 receptor: from neuroanatomy to neuropsychiatry.” InvitedSpeaker, The Department of Pharmacology, The University of Texas Health SciencenCenter at San Antonio. San Antonio Texas.October 22, 1999, “Distribution and regulation of D 3 receptors in Parkinon’s Disease.” InvitedSpeaker, 6 th National Parkinson Foundation International Symposium on Parkinson’sResearch, Miami Florida, USA.January 11, 2000, “The dopamine D 3 receptor from neuroanatomy to potential target forantiparkinsonian drugs.” Invited Speaker, The Parkinson’s Institute, Sunnvale CA, USA.May 12, 2000, “The dopamine D 3 receptor from neuroanatomy to potential target forantipsychotic drugs.” Invited Speaker, Workshop: Schizophrenia: Pathological Bases andMechanisms of Antipsychotic Action, Organized by Institute de RecherchesInternationales Servier, Chicago IL.May 19, 2000, The dopamine D 3 receptor: from neuroanatomy to potential target forantiparkinsonian drugs.” Invited Speaker, Unité de Recherche en Neuroscience, Centerede Recherche, Center Hospitalier Universitaire due Québec, Québec Canada.24
Jeffrey N. Joyce, Ph.D. December 2012May 31, 2000, The dopamine D 3 receptor: from neuroanatomy to potential target forantiparkinsonian drugs.” Invited Speaker, Rush University, Department of Pharmacology,Chicago IL.April 25, 2001, The dopamine D 3 receptor as a therapeutic target for antiparkinsonian drugs.”Invited Speaker, University of Tennessee, Department of Pharmacology, Memphis, TN.April 30, 2001, “Neuroprotection by Antiparkinsonian Drugs: basic and clinical research.”Invited Speaker, Cellular and Molecular Biology Series, Arizona State University, TempeAZ.April 12, 2002, “The dopamine D 3 receptor as a therapeutic target for antipsychotic drugs.”Invited Speaker, Pfizer Pharmaceuticals, Groton CT.May 1, 2002, “Neuroprotection by D 3 preferring agonists: basic and clinical research.” InvitedSpeaker, Pharmacology Department, University of San Antonio, San Antonio TX.September 18, 2002, “Neuroprotective properties of pramipexole in vitro and in vivo.” InvitedSpeaker, Pharmacology Department, Pharmacia Corporation, Kalamazoo MI.September 24, 2002,” Neuroprotective properties of D3 agonists in vitro and in vivo.” InvitedSpeaker, Pharmacology Department, University of North Texas Health Science Center atFort Worth, Fort worth TX.February 27-28, 2003, “Dopamine D3 partial agonists as therapeutic target in PD.” InvitedParticipant, Expert Workshop in Therapeutic Targets for Treatment of Parkinson'sDisease and Related Disorders, New York, NY, SCHWARZ Biosciences.August 7, 2003, “Mechanisms of neuroprotection for D3 agonists in Parkinson’s disease.”Invited Speaker, The Parkinson’s Disease Task Force, University of California at Irvine,Irvine CA.September 18, 2003, “Mechanisms of neuroprotection for D3 agonists in Parkinson’s disease.”Invited Speaker, Intitut de Recherches Servier, Suresnes, FranceSeptember 24, 2003, Chair, Interface track, “The dopamine D3 receptor and its ligands:Therapeutic implications.” 16 th European College of NeuropsychopharmacologyCongress, Prague, Czech Republic.March 25, 2004, , “Mechanisms of neuroprotection for D3 agonists in Parkinson’s disease.”Invited Speaker, Eli Lilly and Company, Indianapolis, IN.May 3, 2004, “Mechanisms of Neuroprotection Using Antiparkinsonian Agents.” InvitedSpeaker, Wyeth Research, Princeton, NJ.May 11, 2004, "Mechanisms of cell death by toxins in terminally differentiated SH-SY5Y cellsand neuroprotection by dopamine agonists." Invited Speaker, Barrow Neurologic InstituteNeuroscience Conference, Phoenix, AZ.25
- Page 1 and 2: Office AddressVice President, Divis
- Page 3 and 4: Jeffrey N. Joyce, Ph.D. December 20
- Page 5 and 6: Jeffrey N. Joyce, Ph.D. December 20
- Page 7 and 8: Jeffrey N. Joyce, Ph.D. December 20
- Page 9 and 10: Jeffrey N. Joyce, Ph.D. December 20
- Page 11 and 12: Jeffrey N. Joyce, Ph.D. December 20
- Page 13 and 14: Jeffrey N. Joyce, Ph.D. December 20
- Page 15 and 16: Jeffrey N. Joyce, Ph.D. December 20
- Page 17 and 18: Jeffrey N. Joyce, Ph.D. December 20
- Page 19 and 20: Jeffrey N. Joyce, Ph.D. December 20
- Page 21 and 22: Jeffrey N. Joyce, Ph.D. December 20
- Page 23: Jeffrey N. Joyce, Ph.D. December 20
<strong>Jeffrey</strong> N. <strong>Joyce</strong>, Ph.D. December 20<strong>12</strong>Symposium on Cerebral Glood Flow & Metabolism, Baltimore MD.April 21, 1998, “Dopamine D3 receptor as a target <strong>of</strong> antipsychotics, “ Invited speaker,Neurosciences Program, <strong>University</strong> <strong>of</strong> Michigan, Ann Arbor, MI.July 16, 1998, “Molecular substrates <strong>of</strong> neurochemical disturbances in schizophrenia, “Symposium Chair, XXI CINP Congress, Glasgow Scotl<strong>and</strong>.July 21, 1998, “Extrapyramidal symptoms in Alzheimer’s disease: Underlying mechanisms,”Invited Speaker, Molecular <strong>and</strong> Cellular Biology Lecture Series, <strong>University</strong> <strong>of</strong>Manchester, Manchester Engl<strong>and</strong>July 25, 1998, “Dopamine D3 receptors: Ontogeny <strong>and</strong> alterations in schizophrenia,” InvitedSpeaker, DA ’98, Strasbourg France.September 28, 1998, “Extrapyramidal symptoms in Alzheimer’s disease: Underlyingmechanisms,” Invited Speaker, Molecular <strong>and</strong> Cellular Biology Lecture Series, ArizonaState <strong>University</strong>, Tempe AZOctober 18-21, 1998, “D 3 receptors <strong>and</strong> the actions <strong>of</strong> neuroleptics in the ventral striatopallidalsystem <strong>of</strong> schizophrenics,” Invited Speaker, New York Academy <strong>of</strong> SciencesConference, Advancing From the Ventral Striatum to the Extended Amygdala:Implications for Neuropsychiatry <strong>and</strong> Drug Abuse, Charlottesville, VirginiaOctober 31- November 4, 1998, “Segregation <strong>and</strong> co-expression <strong>of</strong> D 2 <strong>and</strong> D 3 receptors in thebrain <strong>of</strong> schizophrenic patients: postmortem studies,” Invited Speaker, Symposia: TheDopamine Hypothesis <strong>of</strong> Schizophrenia Revisited, European College <strong>of</strong>Neuropschopharmacology, Paris, FranceMarch 16, 1999, “The dopamine D 3 receptor: from neuroanatomy to neuropsychiatry.” InvitedSpeaker, The Department <strong>of</strong> Pharmacology, The <strong>University</strong> <strong>of</strong> Texas Health SciencenCenter at San Antonio. San Antonio Texas.October 22, 1999, “Distribution <strong>and</strong> regulation <strong>of</strong> D 3 receptors in Parkinon’s Disease.” InvitedSpeaker, 6 th National Parkinson Foundation International Symposium on Parkinson’sResearch, Miami Florida, USA.January <strong>11</strong>, 2000, “The dopamine D 3 receptor from neuroanatomy to potential target forantiparkinsonian drugs.” Invited Speaker, The Parkinson’s Institute, Sunnvale CA, USA.May <strong>12</strong>, 2000, “The dopamine D 3 receptor from neuroanatomy to potential target forantipsychotic drugs.” Invited Speaker, Workshop: Schizophrenia: Pathological Bases <strong>and</strong>Mechanisms <strong>of</strong> Antipsychotic Action, Organized by Institute de RecherchesInternationales Servier, Chicago IL.May 19, 2000, The dopamine D 3 receptor: from neuroanatomy to potential target forantiparkinsonian drugs.” Invited Speaker, Unité de Recherche en Neuroscience, Centerede Recherche, Center Hospitalier Universitaire due Québec, Québec Canada.24
Change language